Our Approach
Enzyme Technology
Engineered Biological Solutions for Infection Control
Developing enzyme based and immunomodulatory technologies for antimicrobial resistance, chronic infections, and viral exposure across human and veterinary health.
The Challenge
Conventional antimicrobial therapies are built on chemical inhibition of microbial targets. While this paradigm has transformed modern medicine, it faces increasing limitations in complex and resistant infections.
Many high-priority pathogens are protected by structural barriers, biofilm communities, and intracellular persistence that restrict drug access and reduce durability of response. In these settings, improvements in chemical potency alone often fail to translate into meaningful clinical gains.
As antimicrobial resistance expands globally, therapeutic strategies must evolve beyond potency alone to address structural and biological barriers that limit treatment effectiveness.
Key Limitations of Current Antimicrobial Strategies
Antimicrobial Resistance
Increasing resistance reduces the effectiveness of existing treatment options worldwide.
Biofilm Protection
Biofilm-associated communities restrict drug access and promote persistent infection.
Non-Specific Activity
Broad-spectrum approaches may disrupt host microbiology without fully resolving infection.
Intracellular Persistence
Certain pathogens survive within host cells, reducing exposure to systemic therapies.
Structural Barriers
Pathogens such as mycobacteria possess complex cell envelopes that limit antibiotic penetration
Approach
Our Approach
ZymIQ Biopharma develops biologically engineered solutions designed to operate within the structural and biological context of infection.
Rather than relying solely on chemical inhibition, our technologies are built to:
  • Target conserved pathogen structures
  • Act catalytically rather than stoichiometrically
  • Enhance access for existing therapies
  • Reduce selective resistance pressure
  • Enable localized intervention formats
Core Focus Area
Enzyme Engineering
Targeted enzymes that degrade structural pathogen barriers
Therapeutic Enhancement
Biological strategies that enhance existing antimicrobial therapies
Immune Modulation
Immune modulating strategies for infection driven inflammation
Localized & Mucosal Intervention
Mucosal and topical formats for targeted delivery
Pipeline
Our Development Programs
ZymIQ Biopharma is advancing a focused pipeline addressing key unmet needs in infection control across human and veterinary medicine.
Mycolyse
A phage-derived, enzyme-based therapeutic platform targeting drug-resistant mycobacterial infections. Mycolyse is designed to structurally degrade the mycobacterial cell envelope, enhancing bacterial clearance and improving the effectiveness of existing therapies in complex diseases such as tuberculosis and nontuberculous mycobacterial (NTM) lung infection.
Stapholyse
An engineered enzyme strategy targeting pathogenic Staphylococcus species. Stapholyse aims to provide a precision antimicrobial approach for human and veterinary AMR infections.
SPL
A phage-derived immunomodulatory biologic for chronic, infection-driven skin disease. SPL promotes immune tolerance to staphylococcal antigens, reducing inflammation without exerting antimicrobial pressure. Originally approved for veterinary and human use, SPL is being redeveloped for canine atopic dermatitis (cAD) and potential human dermatology indications.
ViruPrev
An enzyme-based mucosal barrier platform designed to reduce viral exposure at nasal and oral entry sites. ViruPrev supports local, preventive intervention by targeting pathogens at the point of entry.
Priority Bacterial Targets
ZymIQ Biopharma focuses on high-priority bacterial pathogens identified by global health authorities as urgent threats requiring novel biological solutions.
Pathogenic Mycobacterium Species
Drug resistant and non-tuberculous Mycobacterium species, including M. tuberculosis, M. avium, and M. abscessus, represent major global health challenges across human and animal population.
Pathogenic Staphylococcus Species
Clinically relevant Staphylococcus species, including MRSA and biofilm-associated strains, contribute to persistent infections in both human and veterinary settings.
Viral Threat Landscape
Upper respiratory viruses remain among the most common infectious diseases globally, contributing to seasonal illness, transmission, and secondary complications.
The nasal epithelium represents a primary portal of viral entry and early replication, particularly for respiratory coronaviruses and influenza viruses.
ViruPrev is designed as a local, enzyme-based mucosal barrier intended to reduce viral load at the nasal and throat surfaces, supporting infection control at the point of entry.
Targeted Viral Scope
Respiratory Coronaviruses
Includes SARS-CoV-2 and endemic human coronaviruses associated with common cold infections.
Influenza Viruses
Seasonal and pandemic influenza strains affecting the upper respiratory tract.
Common Cold Viruses
Rhinoviruses and related upper respiratory pathogens transmitted via nasal and throat mucosa.
One Health
One Health Framework for Infection & Antimicrobial Resistance
One Health Perspective
Infections and antimicrobial resistance cross boundaries between humans, animals, and the environment. ZymIQ Biopharma operates within a One Health framework, developing solutions applicable across human medicine, veterinary health, and infection prevention.
Integrated Approach
Solutions designed for cross-species and cross-sector application
Shared Challenges
Addressing infection and resistance through coordinated biological strategies
Broader Impact
Supporting reduced antimicrobial pressure across human and veterinary health
Contact
For partnership discussions, scientific collaboration, or investor inquiries
ZymIQ Biopharma AB
Medicon Village
Scheeletorget 1
223 63 Lund, Sweden